On October 26, 2020 Anpac Bio-Medical Science Co., Ltd. ("Anpac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, reported that it has completed over 200,000 cancer detection tests as of September 30, 2020 using its biophysics based cancer screening technology, Cancer Differentiation Analysis ("CDA") (Press release, Anpac Bio, OCT 26, 2020, View Source [SID1234569063]).The CDA technology allows cancer screening for close to 60 types of cancer, including certain cancer types such as esophageal cancer and brain tumors which do not yet have other more-established blood based testing methods.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As of June 30, 2020, the Company completed an accumulated number of CDA-based tests to 180,673. Since then, Company has carried out over 20,000 additional tests by the end of September, bringing the total number of tests over 200,000.

Dr. Chris Yu, CEO and Chairman of Anpac Bio commented, "We are very pleased to have achieved this milestone of over 200,000 completed biophysics based CDA tests. The rapid increasing number of tests we have achieved indicates the viability and popularity of our products, and indicates that biophysics based cancer screening technology can be an effective alternative approach to traditional cancer screening methods due to its advantages in a number of critical areas, including the detection of multiple cancer types at earlier stages due to a high level of sensitivity and specificity and low cost approach."